Introduction
Crohn's disease
REMISSION, CROHN'S DISEASE
Therapeutic strategies for Crohn's disease have evolved over the past decade with mounting evidence that achieving deep remission (defined as clinical, biochemical, and endoscopic remission) is associated with better long-term outcomes.We report the results of a randomised controlled trial comparing the relapse rate and time spent in remission over 2 years in patients with Crohn's disease in clinical remission under combination therapy who were randomly assigned to one of the following groups: continuation of combination therapy of infliximab and immunosuppressant therapy, or withdrawal of infliximab, or withdrawal of immunosuppressant therapy.
